1stOncology™: Cancer Intelligence Service – Page 816 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

On September 2, 2025 Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, reported that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 (Press release, Aligos Therapeutics, SEP 2, 2025, View Source [SID1234655629]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A webcast of the on demand presentation will be accessible by visiting the Presentation & Events section on the "Investors" page of Aligos’ website at www.aligos.com. A replay of the webcast will be available following the presentation for at least 30 days.

Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NARMAFOTINIB ADOPTED AS NONPROPRIETARY DRUG NAME IN USA

On September 1, 2025 Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") reported that the United States Adopted Names (USAN) Council has adopted the name narmafotinib as the generic drug name for the Company’s lead FAK inhibitor currently undergoing clinical studies in pancreatic cancer (Press release, Amplia Therapeutics, SEP 1, 2025, View Source [SID1234655616]).

Amplia has previously reported that the World Health Organization (WHO) approved narmafotinib as the International Non-Proprietary Name (INN) for global use1. The USAN council’s adoption of the name narmafotinib is a separate process that formalises the nonproprietary name for the molecule in the United States.

Dr Chris Burns, Amplia’s CEO and Managing Director commented: "We are delighted that the USAN council have adopted the name narmafotinib. Obtaining a USAN is an essential step for any drug molecule intended for the US market, and it represents an important step in the drug’s commercial development as we begin our trial of narmafotinib in the USA."

TME Pharma Completes August Financing and Publishes Cash Position

On September 1, 2025 TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, reported that the transaction announced last August 25th has now been completed with €500k in cash received by the Company August 28th (Press release, TME Pharma, SEP 1, 2025, View Source [SID1234655614]). The cash position of TME Pharma is up to €2.35M, showing the good progress of the new cost-efficient organization.

Now that TME Pharma has implemented the lower cost-base model, it will be more able to attract partners for the development of new therapies for cancer and eye diseases. TME Pharma still has high expectations for its NOX-A12 and NOX-E36 programs. TME Pharma will keep informing the markets about the progress it is making.

CEO Van den Ouden will continue to use his experience and expertise to implement the Company’s treasury investment strategy to properly balance risk and return to achieve optimal results for shareholders. TME Pharma is continuing to search for suitable crypto and crypto related candidates for the treasury investment strategy but has no current exposure to crypto.